Trial Profile
A Safety and Efficacy Study of CT-Guided Adaptive Radiation Therapy With Anti-PD-1 Antibody Adjuvant Immunotherapy in Patients With Thoracic Cancer (CARTAI)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Sintilimab (Primary)
- Indications Non-small cell lung cancer; Thoracic neoplasms
- Focus Adverse reactions
- Acronyms CARTAI
- 31 Jan 2021 Results (n=15) presented at the 2020 World Conference on Lung Cancer
- 15 Nov 2018 New trial record
- 14 Nov 2018 Status changed from not yet recruiting to recruiting.